Laurent Pharmaceuticals receives health Canada’s approval to initiate COVID-19 clinical trial
Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate RESOLUTION, a Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential drug candidate to help combat the COVID-19 disease. The trial, which is planned to start imminently in multiple hospitals in Canada, will enroll approximatively 200 hospitalized COVID-19 patients for a treatment duration of 14 days.
